Jump to content
  • Professionals’ Networked Community Platform; Cannabis Connect™

    Cannabis Connect™ is the leading Professionals’ Networked Community (PNC) platform for Cannabis and Hemp value chain organizations, the management and workforces which run them, their partners, suppliers and customers which support and interact with them.

    Join Us

    Member Tiers

    Our Professionals’ Networked Community (PNC) platform, Cannabis ConnectTM, is organized using five (5) levels, or tiers.

    Each Tier has a specific orientation and strength, as well as a set of unique functions and capabilities.

    As you progress from one Tier to another, you gain access to additional States (or Territories, Provinces and Countries) based on which Member organization you start with.

    Read More

    Ducats & Alms™

    A Cannabis Connect™ Gaming System

    We have embedded the Ducats and Alms™ gaming system within our Cannabis Connect™ platform. This section covers the basic Game Rules & Game Shop Pavilion objectives. We invite our Members to help us fine tune this unique game and move it towards a more broad-based content and knowledge management system which grows everyones’ knowledge, skills and competencies.

    Read More

    American Members

    The American Association of Cannabis & Hemp (C+H) Value ChainsTM serves the herbal wellness and Cannabis and Hemp industries as well as addressing many other herbal wellness topics and knowledge management activities. We even have a Knowledge Management game called Ducats & AlmsTM, which makes it fun to work and discuss herbal wellness and value chain topics with others!

    Read More

    Canadian Members

    The Canadian Association of Cannabis & Hemp (C+H) Value ChainsTM serves the herbal wellness and Cannabis and Hemp industries as well as addressing many other herbal wellness topics and knowledge management activities. We even have a Knowledge Management game called Ducats & AlmsTM, which makes it fun to work and discuss herbal wellness and value chain topics with others!

    Read More

    International Members

    The International Association of Cannabis & Hemp (C+H) Value ChainsTM serves the herbal wellness and Cannabis and Hemp industries as well as addressing many other herbal wellness topics and knowledge management activities. We even have a Knowledge Management game called Ducats & AlmsTM, which makes it fun to work and discuss herbal wellness and value chain topics with others!

    Read More
  • Recent Status Updates

    No Recent Status Updates
  • Posts

    • MemberSupport

      Posted

      EXCITING NEWS from our favorite C+H pharma venture!

       

      Greetings Fellow Shareholders,

      I hope this note finds everyone well!

      As we settle into the new year, I wanted to wish everyone and their families a healthy and prosperous 2023 on behalf of our team at Shackelford Pharma. I am pleased to share with you a brief but very significant update to start the year.

      As you are aware, our initial focus is the field of epilepsy, based upon Dr. Shackelford’s real-world experience and the considered opinion of our world-class R&D team. This database that Dr. Shackelford has generated, by treating many patients suffering from epileptic conditions, is amongst the most valuable assets in our portfolio. I’m delighted to share with you these very recent and very exciting results derived from his real-world database of more than 25,000 patient interactions.

      7ddb31da-3871-f8da-1db5-07f4ca2e5606.jpg

       

      Patients taking Dr. Shackelford’s cannabinoid-based treatment (we are calling it SP1707) for at least one year resulted in clinically significant positive outcomes in adult and pediatric patients with a specific seizure type (our first indication). The analysis of results (as of January 12, 2023) is shown in the table below. (Published data from Jazz Pharmaceutical Inc.’s cannabidiol (“CBD”) based product, EPIDIOLEX®, is shown as a comparator.)

      Here are the key insights from this analysis:

      • Cumulatively, we have collected over 350 patient years of real-world data in epilepsy from Dr. Shackelford’s database. Patients, both adult and children, had been suffering from epilepsy for up to 46 years, and 16 years respectively, prior to being treated with the active ingredient in our drug candidate (SP1707), suggesting that this has been a treatment for a hard-to-treat population of patients. 
      • Responder rates (meaning the percentage of patients who responded to treatment that had at least a 50% reduction in seizure frequency over a 1-year treatment period) were 71% in adults and 60% in pediatrics — which is aligned with the response rates initially seen with the [now] commercially available epilepsy drugs such as FINTEPLA® (fenfluramine) open label studies, and better than those observed with the CBD based drug EPIDIOLEX®. 
      • Importantly, one-year seizure remission rates (patients without a seizure for a year), were similar between adults (44%) and children (40%), and were greater than those observed with EPIDIOLEX®.  Compared to baseline or expected one-year seizure remission rates for this type of seizure, SP1707 elicited an approximate 9-fold improvement
      • The safety and tolerability data for SP1707 has been positive, with only 2% of adult patients and no children reporting any adverse events. This compares favorably to EPIDIOLEX® and other FDA approved antiepileptic medicines.

       

      6c2440f7-bb15-87a0-11ba-7502d0b1af89.jpg

       

      9bed0b2d-5367-46bd-2f38-fa4d92dc84c5.jpg

      KEY:
      EAP: Expanded Access Program      RCT: Randomized Controlled Trials        SZ: Seizures    
      N/A: Not Available                             LGS: Lennox-Gastaut Syndrome             DS: Dravet Syndrome
      TSC: Tuberous Sclerosis Complex   TRE: Treatment Resistant Epilepsy   
      SP1707 is the development name/number of the Company's first drug candidate undergoing clinical development that contains the active ingredient used by Dr. Shackelford in his real-world experience treating patients. The initial Phase 2 study of SP1707 in epilepsy patients will use an immediate-release oral formulation of SP1707 that will mimic the release characteristics of the cannabinoid that Dr. Shackelford used in treating his patients. Ultimately SP1707 is being developed as a proprietary extended-release oral cannabinoid formulation that is amenable to being dosed once daily in patients.

      Bringing all this data to life is one of the best Pharma development teams around. In almost all business, it is always about the team. In our case we are not only fortunate to have all of Alan’s clinical data and results but also a Pharma development team that is second to none.

      “This analysis of Dr. Shackelford’s real-world experience strongly supports our reason to believe we have a path to Phase 2 clinical trials. This exciting human efficacy and safety data will be used to support our Investigational New Drug (“IND”) submission to the FDA. The observed 9-fold improvement in 1 year seizure remission rates over what is typically expected in this seizure type gives us confidence that we may see clinically significant effectiveness when we progress into Phase 2. Importantly, this retrospective data seems to be tracking closely with what was observed with FINTEPLA® (fenfluramine) in open label studies and better than those observed with EPIDIOLEX®”.

      Dr. Susan Learned, Head of R&D at Shackelford.

      Given there is much to discuss here, we expect to follow this update with an open invitation investor webinar, which we aim to host this quarter. It will feature members of our executive and R&D team, and allow for detailed discussion of these findings, along with opportunities for Q&A.

       

      36367d29-0137-bedc-de2f-97373b4e1e6c.jpg

      As Sue has said, our primary focus now is to prepare for the start of a Phase 2 trial with our patent-pending epilepsy drug candidate, SP1707. We expect the trial to start this year (subject to funding) and following the FDA’s endorsement of our IND, which is also expected to be submitted in the 2nd half of 2023. This trial will focus on a portion of the epilepsy population where current medications fall short. Most anti-epileptic drugs have varying degrees of efficacy with about 36% of patients not responding well to their medication, resulting in uncontrolled seizure activity. There are approximately 50 million people with epilepsy around the world, with an estimated 5 million more added every year, which means many people suffering from epilepsy are left looking for an effective treatment.

      Our hope and expectation, based upon Dr. Shackelford’s real-world experience as shared above, is that patients may be able to replace, reduce or potentially eliminate the traditional drugs they are taking (which in many cases, have terrible side effects). 

      In 2023, we will also be looking to expand our Board of Directors to support our incredible team. Our mission has attracted the best of the best and we anticipate that we will be adding the same quality of individuals to our board. We hope to add additional experience to supplement our incredible R&D team led by Dr. Susan Learned, and our Scientific Advisory Board — which includes some of the world’s leading epileptologists, (including the person who set the standards for epilepsy within the FDA), the individual responsible for de-scheduling CBD in the USA, and our world class experts on the endocannabinoid system.

      Following our initial meeting with the FDA last September, we are now preparing the critical work necessary for filing the IND application to the FDA sometime in the second half of this year. Assuming endorsement by the FDA, we will then be allowed to start our Phase 2 clinical trial.

      Thank you again Dr. Shackelford for all your incredibly pioneering work, and the skillful devotion of our R&D team for making all this possible! As we progress this year, you will be the first to know, so keep an eye on your inbox for our shareholder updates.

      234b7545-4d08-179b-0ba4-aeca73156ba2.jpg

      Our R&D Team had a very busy year - here are some of the highlights:

      • Completed full due diligence on the company portfolio priorities and associated recommendations based on that due diligence;
      • Completed scientific and clinical assessments to determine a prioritized portfolio project;
      • Recruited a world-class R&D team and Scientific Advisory Board (“SAB”);
      • Worked with our intellectual property lawyers, drafting, and filing a provisional patent supporting our prioritized portfolio project within company-requested timelines;
      • Performed RFP (Request for Proposal) and due diligence assessments for selection of a Phase 2 supply clinical development partner;
      • Performed substantial due diligence and IP evaluations on potential final proprietary formulation options (and clinical development partners) and initiated a 3-prong strategy to identify and progress proof of concept protypes;
      • Led formation of a formal Disclosure Committee within Shackelford;
      • Completed all preclinical, Chemistry, Manufacturing and Controls (“CMC”) and clinical Pre-IND (Investigational New Drug)-enabling activities and reports, including conducting of a comprehensive preclinical literature search on effects of SP1707 in epilepsy;
      • Together with Shackelford’s SAB, designed and drafted a Phase 2 protocol synopsis for inclusion in the Pre-IND briefing book for the FDA;
      • Prepared for and held two critical SAB meetings based upon feedback received from FDA with respect to our Pre-IND package, resulting in several ongoing actions to improve the submission for the upcoming IND;
      • Established further enhancements for provisional patent strength and augmenting future clinical investigator engagement;
      • Conducted third-party, independent company valuation for forthcoming financing;

      And of course, of greatest importance:

      • Completed a deep data dive on additional real-world experience from Dr. Shackelford’s patient records which produced strong evidence of the potential of SP1707 and gave us further insights into other potential indications beyond our initial target.

      dd5a156d-fa66-b944-8ed9-77e1c233a747.jpg

      Developing an actual medicine that medical doctors prescribe is an extremely expensive exercise as you know. If successful, however, medicines are amongst the most valuable assets anyone can own, which is why pharmaceutical companies are amongst the most valuable companies in the world.

      In our case, we are most fortunate to have Dr. Shackelford’s real-world experience. A significant portion of the expense in drug development is found in the discovery process, which generally happens in a chemistry lab. As you know, we are unique. Thanks to Dr. Shackelford’s work, our discoveries come from actual patient interactions from his medical practice. However, the next stage, which is the regulatory pathway, is expensive, and this path is determined by the FDA.

      Our Phase 2 trial will cost approximately $30 million. This covers the manufacture of clinical trial supplies, which is significant. It also encompasses all the necessary work establishing trial sites and enrolling participants into the trial based upon the criteria accepted by the FDA and Institutional Review Boards. Our trial is expected to run approximately 24 months, with interim results announced halfway through the trial.

      Our plan is to tackle this funding requirement in two steps, starting with a Regulation A crowdfunding round, just like our initial financing. We expect this new round will launch in the coming days. As investors in Shackelford, we will open this new offering to our existing shareholders first, so please keep your eyes open for our next email, where we expect to share more details along with an invitation to participate if you wish1.

      In anticipation of this financing, we engaged a respected international firm that focuses specifically on pharmaceutical company valuations. This independent, 3rd-party opinion valued our company between USD $70-million and USD $187 million. Recognizing the soft macro market conditions that have affected the capital markets over the last year, we chose to value our company at the lower end of this valuation, and set the price at USD $1.50 per share, which correlates to a pre-raise market cap of about USD $70-million.

      Our Regulation A funding round will be open for up to a total of USD $12 million.

      We are working on the balance of the funding by targeted institutional investors and funds, and we are in discussions with several parties who are interested in our target indication, our team and our approach, and have started due diligence to learn more about Shackelford and the opportunity. While we are committed to helping as many people as we can who suffer from epilepsy, we are also committed to making sure that our shareholders have an opportunity to benefit from the increase in value of our Company as we progress as well. This may be as a private, or public entity, depending upon how we can best raise capital and maximize shareholder value.

      As mentioned above, we will be hosting an investor webinar early this year, where I will invite key members of our team to attend. This will allow anyone who attends the opportunity to hear directly from the Shackelford team, and more importantly, provide a venue to ask questions and learn more about what I have described above. I hope you are all able to join us. We’ll be sure to record it and share it as well if you cannot.

      THANK YOU again, to each of you reading this and for your support, without which we would not be here. We are on the precipice of an exciting new chapter in our Company’s development, and we owe much of this progress to you.

      On behalf of YOUR team, I wish everyone an incredible 2023!!

      Onwards!!

      ed8ce33a-4add-cd97-12b9-e1183ee248df.jpg

      Mark Godsy
      Co-Founder, CEO and Chairman

       

      Contact US  

      If you have any questions or wish to connect for any reason, please feel free to reach out to us via email at investors@shackelfordpharma.com or by calling us at 1-888-377-4225 Ext.1.


      Thank you for taking the time to read our update - and for your ongoing support of Shackelford Pharma.

      [1] This is not an offer for sale of shares. Appropriate offering documents will be issued when a financing is launched.

      Shackelford Pharma.PNG

       

      image.png

    • MemberSupport

      Posted

      This article was written by Tori Bedford on January 5th, 2023. Thanks, Tori!

      While the state’s marijuana business continues to boom, cannabis growers in Massachusetts — already facing tough business setbacks in a competitive and volatile market — are scrambling to ward off a rapidly spreading and highly infectious crop disease, one with the power to wipe out entire companies.

      “It’s like the tenth plague for the cannabis industry,” said Peter Grinspoon, a medical cannabis specialist at Massachusetts General Hospital. “The margins are drying up for anybody growing cannabis. They need this like they need a hole in the head. It’s a nightmare.”

      Hop latent viroid, a plant-specific pathogenic RNA, sucks the THC potency out of cannabis plants, degrading the quality and resulting in significantly smaller yields. It's sometimes referred to as "dudding disease."

      The pathogen has already blighted California’s cannabis crops, resulting in $4 billion annual losses, according to cannabis genetics research company Dark Heart Industries. The pathogen has no known effect on human health, though Grinspoon and other experts say very little research exists.

      Grinspoon says the disease is causing a “total evolution” in the cannabis industry, as manufacturers are forced to adopt more stringent measures to combat it. Their prevention efforts include more rigorous sanitation in grow facilities, regular lab testing, and sourcing plants from pre-tested seed or local stock — steps that come at a cost.

      “If you were cutting corners, I’m sure you have stopped cutting them by now,” Grinspoon said. “It’s not in your economic interests to cut corners when something like this is spreading from crop to crop.”

      Where cost-cutting may come back to haunt growers
      Ed DeSousa, who owns the small wholesale grow facility River Run Gardens in Newburyport, said growers who have always been meticulous about their product have less to worry about. The companies facing the greatest threat now, he said, are the ones that tried to save money by importing “clones” of trendy, out-of-state variants or fell behind on testing and sanitization.

      “Those who decided to take those shortcuts to try to make some money, it's almost like cannabis karma,” DeSousa said. “If you go into this particular line of business and you are looking to maximize your profit at the stake of putting out a solid product, well, this was bound to happen.”


      The virus can be detected through a genetic PCR test, a step that is not required by the Cannabis Control Commission.

      By the time growers notice the signs — stunted and brittle plants, lower THC levels and discolored leaves — it’s too late to stop the spread, Masso said. By that point, growers are essentially left with one option, said Nick Masso, the CEO of Marlborough-based Indo Laboratories, an independent marijuana testing facility.

      “Destroy it. Destroy everything,” he said. “And if you had that anywhere within your facility, you need to do an extremely deep clean. You can’t sell a low-quality product that has no THC, and no one will buy it.”

      On a federal level, cannabis remains illegal, and shipping plants across state lines is prohibited by state law. A gray area in the regulations allows growers to acquire seeds and trimmings or “immature plants” (non-flowering and under eight inches tall) from out-of-state and disclose the plants once they reach the propagation stage.

      “Typically no one really starts with seeds anymore. People usually will get clones from someone to have a little bit more of an advanced starting point,” Masso said. “There are companies out there that get seeds, but they're not always doing genetic testing.”

      A call for stricter cannabis regulation
      Since recreational marijuana was legalized in Massachusetts seven years ago, the industry has accelerated at a breakneck pace, Masso said, with regulators “lacking the bandwidth” to apply additional — and necessary — scrutiny.

      “A lot of it depends on how much effort these companies are willing to put in to actually make sure that they’re being safe in what they’re putting out into the market,” Masso said.

      A 2018 Harvard study demonstrated inaccurate and wildly varied results from state-certified marijuana testing facilities in Washington state. An investigation conducted last year by journalists from Commonwealth Magazine showed inconsistencies in levels of THC and contaminants present in cannabis sold in Massachusetts.

      The spread of hop latent viroid is a call to action for companies — and regulators — who have let protocols fall through the cracks in recent years, Masso said. Now, companies that didn’t want to play by the rules face serious consequences.

      “There’s something very poetic about it,” he said. “I don’t take pleasure in other people's misfortune, but sometimes there's companies out there that deserve it. I just hope that someone doesn't have to get hurt for them to learn their damn lesson.”

      Masso says regulation is vital in a market where many companies may just not know better, making mistakes without realizing the potential consequences. He works with 35 clients around the state, and says his lab has detected hop latent viroid at three locally-based marijuana grow facilities in the past three years.

      “I’m suspicious that there are many, many more companies that have experienced this, because you’ll see the THC levels drop from the twenties to the teens,” Masso said. “It doesn’t feel like enough people in the industry understand the gravity of what this could mean.”

      Massachusetts law requires marijuana testing labs to be accredited through a process that requires audits, background checks and quality assurance tests, but labs aren’t required to receive accreditation for every single test they conduct, Masso says.

      “Every single thing that we do is accredited, but the clients don't know any different when it comes to labs,” he said. “That leaves a lot of room for bad actors to come into the space who don't give a damn about the science, they just want to make money.”

      The state’s cannabis production industry is now the highest valued agricultural crop at $362 million annual wholesale value, according to trade publication.

      Masso says his hope is that the financial threat from hop latent viroid will force the industry to focus on consumers who use marijuana for medical purposes and could suffer if products fall off the market.

      “The cannabis industry built itself on being medicinal, that’s where it got its roots,” he said. “Now it's become just a commodity and people have forgotten that it was all about treating patients, not just about getting people high and making money.”

    • MemberSupport

      Posted

      Article by Tori Bedford; January 5th, 2023

      While the state’s marijuana business continues to boom, cannabis growers in Massachusetts — already facing tough business setbacks in a competitive and volatile market — are scrambling to ward off a rapidly spreading and highly infectious crop disease, one with the power to wipe out entire companies.

      “It’s like the tenth plague for the cannabis industry,” said Peter Grinspoon, a medical cannabis specialist at Massachusetts General Hospital. “The margins are drying up for anybody growing cannabis. They need this like they need a hole in the head. It’s a nightmare.”

      Hop latent viroid, a plant-specific pathogenic RNA, sucks the THC potency out of cannabis plants, degrading the quality and resulting in significantly smaller yields. It's sometimes referred to as "dudding disease."

      The pathogen has already blighted California’s cannabis crops, resulting in $4 billion annual losses, according to cannabis genetics research company Dark Heart Industries. The pathogen has no known effect on human health, though Grinspoon and other experts say very little research exists.

      Grinspoon says the disease is causing a “total evolution” in the cannabis industry, as manufacturers are forced to adopt more stringent measures to combat it. Their prevention efforts include more rigorous sanitation in grow facilities, regular lab testing, and sourcing plants from pre-tested seed or local stock — steps that come at a cost.

      “If you were cutting corners, I’m sure you have stopped cutting them by now,” Grinspoon said. “It’s not in your economic interests to cut corners when something like this is spreading from crop to crop.”

      Where cost-cutting may come back to haunt growers
      Ed DeSousa, who owns the small wholesale grow facility River Run Gardens in Newburyport, said growers who have always been meticulous about their product have less to worry about. The companies facing the greatest threat now, he said, are the ones that tried to save money by importing “clones” of trendy, out-of-state variants or fell behind on testing and sanitization.

      “Those who decided to take those shortcuts to try to make some money, it's almost like cannabis karma,” DeSousa said. “If you go into this particular line of business and you are looking to maximize your profit at the stake of putting out a solid product, well, this was bound to happen.”


      The virus can be detected through a genetic PCR test, a step that is not required by the Cannabis Control Commission.

      By the time growers notice the signs — stunted and brittle plants, lower THC levels and discolored leaves — it’s too late to stop the spread, Masso said. By that point, growers are essentially left with one option, said Nick Masso, the CEO of Marlborough-based Indo Laboratories, an independent marijuana testing facility.

      “Destroy it. Destroy everything,” he said. “And if you had that anywhere within your facility, you need to do an extremely deep clean. You can’t sell a low-quality product that has no THC, and no one will buy it.”

      On a federal level, cannabis remains illegal, and shipping plants across state lines is prohibited by state law. A gray area in the regulations allows growers to acquire seeds and trimmings or “immature plants” (non-flowering and under eight inches tall) from out-of-state and disclose the plants once they reach the propagation stage.

      “Typically no one really starts with seeds anymore. People usually will get clones from someone to have a little bit more of an advanced starting point,” Masso said. “There are companies out there that get seeds, but they're not always doing genetic testing.”

      A call for stricter cannabis regulation
      Since recreational marijuana was legalized in Massachusetts seven years ago, the industry has accelerated at a breakneck pace, Masso said, with regulators “lacking the bandwidth” to apply additional — and necessary — scrutiny.

      “A lot of it depends on how much effort these companies are willing to put in to actually make sure that they’re being safe in what they’re putting out into the market,” Masso said.

      A 2018 Harvard study demonstrated inaccurate and wildly varied results from state-certified marijuana testing facilities in Washington state. An investigation conducted last year by journalists from Commonwealth Magazine showed inconsistencies in levels of THC and contaminants present in cannabis sold in Massachusetts.

      The spread of hop latent viroid is a call to action for companies — and regulators — who have let protocols fall through the cracks in recent years, Masso said. Now, companies that didn’t want to play by the rules face serious consequences.

      “There’s something very poetic about it,” he said. “I don’t take pleasure in other people's misfortune, but sometimes there's companies out there that deserve it. I just hope that someone doesn't have to get hurt for them to learn their damn lesson.”

      Masso says regulation is vital in a market where many companies may just not know better, making mistakes without realizing the potential consequences. He works with 35 clients around the state, and says his lab has detected hop latent viroid at three locally-based marijuana grow facilities in the past three years.

      “I’m suspicious that there are many, many more companies that have experienced this, because you’ll see the THC levels drop from the twenties to the teens,” Masso said. “It doesn’t feel like enough people in the industry understand the gravity of what this could mean.”

      Massachusetts law requires marijuana testing labs to be accredited through a process that requires audits, background checks and quality assurance tests, but labs aren’t required to receive accreditation for every single test they conduct, Masso says.

      “Every single thing that we do is accredited, but the clients don't know any different when it comes to labs,” he said. “That leaves a lot of room for bad actors to come into the space who don't give a damn about the science, they just want to make money.”

      The state’s cannabis production industry is now the highest valued agricultural crop at $362 million annual wholesale value, according to trade publication.

      Masso says his hope is that the financial threat from hop latent viroid will force the industry to focus on consumers who use marijuana for medical purposes and could suffer if products fall off the market.

      “The cannabis industry built itself on being medicinal, that’s where it got its roots,” he said. “Now it's become just a commodity and people have forgotten that it was all about treating patients, not just about getting people high and making money.”

    • MemberSupport

      Posted

      LAS VEGAS, NV / ACCESSWIRE / December 5, 2022 / Planet 13 Holdings Inc. (CSE:PLTH) (OTCQX:PLNHF) ("Planet 13" or the "Company"),a leading vertically-integrated multi-state cannabis company, announces that its subsidiary MM Development Company, Inc. has received approval for a Nevada consumption lounge from the Nevada Cannabis Compliance Board ("CCB"). The Planet 13 Entertainment Complex will be the first of its kind space where consumers can watch products being made, purchase and consume all under one roof. This luxurious, tourist friendly lounge, close to the Las Vegas Strip is expected to elevate the already incredible Planet 13 experience.

      "We are thrilled to be moving forward with our plan to bring a world-class cannabis consumption lounge next to the Las Vegas Strip," said Larry Scheffler, Co-CEO of Planet 13. "Planet 13 has always been about offering new and one-of-a-kind immersive experiences for customers. We look forward to once again pushing the envelope and expanding people's minds about what cannabis can be."
      For more information on Planet 13, visit the investor website.

      About Planet 13
      Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations in Las Vegas and in Orange County, California. Planet 13 also holds a medical marijuana treatment center license in Florida and a 49% interest in Planet 13 Illinois which holds a provisional Social-Equity Justice Involved dispensing license in the Chicago-region of Illinois. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13's shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and on the OTCQX under the symbol PLNHF.
      Cautionary Note Regarding Forward-Looking Information

      This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and are forward-looking statements. In this news release, forward looking-statements relate to the Company's design, construction, and operation of a Nevada consumption lounge.

      These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents needed to operate our business; risks associated with COVID-19 and other infectious diseases presenting as major health issues; fluctuations in general macroeconomic conditions; inflationary pressures; fluctuations in securities markets; expectations regarding the size of the cannabis market in the states in which we currently operate in or contemplate future operations and changing consumer habits in such states; the ability of the Company to successfully achieve its business objectives; the ability of the Company to integrate the NGW business and realize any benefits from the acquisition; plans for expansion; political and social uncertainties including international conflict; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the states in which we currently operate in or contemplate future operations; employee relations and other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission at www.sec.gov and on the Company's issuer profile on SEDAR at www.sedar.com and in the Company's periodic reports subsequently filed with the U.S. Securities and Exchange Commission and on SEDAR. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

      The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through licensed subsidiary entities in states that have legalized marijuana operations, however, these activities are currently illegal under United States federal law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
      No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

      For further inquiries, please contact:
      LodeRock Advisors Inc., Planet 13 Investor Relations
      mark.kuindersma@loderockadvisors.com
      Robert Groesbeck or Larry Scheffler
      Co-Chief Executive Officers
      ir@planet13lasvegas.com

      SOURCE: Planet 13 Holdings Inc.
      You can view this article online using the following link: https://www.accesswire.com/730051/Planet-13-Announces-Approval-for-Consumption-Lounge-License-a-Highly-Anticipated-Addition-to-the-World-Renowned-Las-Vegas-SuperStore-Experience
       

    • MemberSupport

      Posted

      Awesome Verticle Farming Units (VFUs)... these will change the nature of the medical C+H industries!

  • Posts

    • MemberSupport

      Posted

      EXCITING NEWS from our favorite C+H pharma venture!

       

      Greetings Fellow Shareholders,

      I hope this note finds everyone well!

      As we settle into the new year, I wanted to wish everyone and their families a healthy and prosperous 2023 on behalf of our team at Shackelford Pharma. I am pleased to share with you a brief but very significant update to start the year.

      As you are aware, our initial focus is the field of epilepsy, based upon Dr. Shackelford’s real-world experience and the considered opinion of our world-class R&D team. This database that Dr. Shackelford has generated, by treating many patients suffering from epileptic conditions, is amongst the most valuable assets in our portfolio. I’m delighted to share with you these very recent and very exciting results derived from his real-world database of more than 25,000 patient interactions.

      7ddb31da-3871-f8da-1db5-07f4ca2e5606.jpg

       

      Patients taking Dr. Shackelford’s cannabinoid-based treatment (we are calling it SP1707) for at least one year resulted in clinically significant positive outcomes in adult and pediatric patients with a specific seizure type (our first indication). The analysis of results (as of January 12, 2023) is shown in the table below. (Published data from Jazz Pharmaceutical Inc.’s cannabidiol (“CBD”) based product, EPIDIOLEX®, is shown as a comparator.)

      Here are the key insights from this analysis:

      • Cumulatively, we have collected over 350 patient years of real-world data in epilepsy from Dr. Shackelford’s database. Patients, both adult and children, had been suffering from epilepsy for up to 46 years, and 16 years respectively, prior to being treated with the active ingredient in our drug candidate (SP1707), suggesting that this has been a treatment for a hard-to-treat population of patients. 
      • Responder rates (meaning the percentage of patients who responded to treatment that had at least a 50% reduction in seizure frequency over a 1-year treatment period) were 71% in adults and 60% in pediatrics — which is aligned with the response rates initially seen with the [now] commercially available epilepsy drugs such as FINTEPLA® (fenfluramine) open label studies, and better than those observed with the CBD based drug EPIDIOLEX®. 
      • Importantly, one-year seizure remission rates (patients without a seizure for a year), were similar between adults (44%) and children (40%), and were greater than those observed with EPIDIOLEX®.  Compared to baseline or expected one-year seizure remission rates for this type of seizure, SP1707 elicited an approximate 9-fold improvement
      • The safety and tolerability data for SP1707 has been positive, with only 2% of adult patients and no children reporting any adverse events. This compares favorably to EPIDIOLEX® and other FDA approved antiepileptic medicines.

       

      6c2440f7-bb15-87a0-11ba-7502d0b1af89.jpg

       

      9bed0b2d-5367-46bd-2f38-fa4d92dc84c5.jpg

      KEY:
      EAP: Expanded Access Program      RCT: Randomized Controlled Trials        SZ: Seizures    
      N/A: Not Available                             LGS: Lennox-Gastaut Syndrome             DS: Dravet Syndrome
      TSC: Tuberous Sclerosis Complex   TRE: Treatment Resistant Epilepsy   
      SP1707 is the development name/number of the Company's first drug candidate undergoing clinical development that contains the active ingredient used by Dr. Shackelford in his real-world experience treating patients. The initial Phase 2 study of SP1707 in epilepsy patients will use an immediate-release oral formulation of SP1707 that will mimic the release characteristics of the cannabinoid that Dr. Shackelford used in treating his patients. Ultimately SP1707 is being developed as a proprietary extended-release oral cannabinoid formulation that is amenable to being dosed once daily in patients.

      Bringing all this data to life is one of the best Pharma development teams around. In almost all business, it is always about the team. In our case we are not only fortunate to have all of Alan’s clinical data and results but also a Pharma development team that is second to none.

      “This analysis of Dr. Shackelford’s real-world experience strongly supports our reason to believe we have a path to Phase 2 clinical trials. This exciting human efficacy and safety data will be used to support our Investigational New Drug (“IND”) submission to the FDA. The observed 9-fold improvement in 1 year seizure remission rates over what is typically expected in this seizure type gives us confidence that we may see clinically significant effectiveness when we progress into Phase 2. Importantly, this retrospective data seems to be tracking closely with what was observed with FINTEPLA® (fenfluramine) in open label studies and better than those observed with EPIDIOLEX®”.

      Dr. Susan Learned, Head of R&D at Shackelford.

      Given there is much to discuss here, we expect to follow this update with an open invitation investor webinar, which we aim to host this quarter. It will feature members of our executive and R&D team, and allow for detailed discussion of these findings, along with opportunities for Q&A.

       

      36367d29-0137-bedc-de2f-97373b4e1e6c.jpg

      As Sue has said, our primary focus now is to prepare for the start of a Phase 2 trial with our patent-pending epilepsy drug candidate, SP1707. We expect the trial to start this year (subject to funding) and following the FDA’s endorsement of our IND, which is also expected to be submitted in the 2nd half of 2023. This trial will focus on a portion of the epilepsy population where current medications fall short. Most anti-epileptic drugs have varying degrees of efficacy with about 36% of patients not responding well to their medication, resulting in uncontrolled seizure activity. There are approximately 50 million people with epilepsy around the world, with an estimated 5 million more added every year, which means many people suffering from epilepsy are left looking for an effective treatment.

      Our hope and expectation, based upon Dr. Shackelford’s real-world experience as shared above, is that patients may be able to replace, reduce or potentially eliminate the traditional drugs they are taking (which in many cases, have terrible side effects). 

      In 2023, we will also be looking to expand our Board of Directors to support our incredible team. Our mission has attracted the best of the best and we anticipate that we will be adding the same quality of individuals to our board. We hope to add additional experience to supplement our incredible R&D team led by Dr. Susan Learned, and our Scientific Advisory Board — which includes some of the world’s leading epileptologists, (including the person who set the standards for epilepsy within the FDA), the individual responsible for de-scheduling CBD in the USA, and our world class experts on the endocannabinoid system.

      Following our initial meeting with the FDA last September, we are now preparing the critical work necessary for filing the IND application to the FDA sometime in the second half of this year. Assuming endorsement by the FDA, we will then be allowed to start our Phase 2 clinical trial.

      Thank you again Dr. Shackelford for all your incredibly pioneering work, and the skillful devotion of our R&D team for making all this possible! As we progress this year, you will be the first to know, so keep an eye on your inbox for our shareholder updates.

      234b7545-4d08-179b-0ba4-aeca73156ba2.jpg

      Our R&D Team had a very busy year - here are some of the highlights:

      • Completed full due diligence on the company portfolio priorities and associated recommendations based on that due diligence;
      • Completed scientific and clinical assessments to determine a prioritized portfolio project;
      • Recruited a world-class R&D team and Scientific Advisory Board (“SAB”);
      • Worked with our intellectual property lawyers, drafting, and filing a provisional patent supporting our prioritized portfolio project within company-requested timelines;
      • Performed RFP (Request for Proposal) and due diligence assessments for selection of a Phase 2 supply clinical development partner;
      • Performed substantial due diligence and IP evaluations on potential final proprietary formulation options (and clinical development partners) and initiated a 3-prong strategy to identify and progress proof of concept protypes;
      • Led formation of a formal Disclosure Committee within Shackelford;
      • Completed all preclinical, Chemistry, Manufacturing and Controls (“CMC”) and clinical Pre-IND (Investigational New Drug)-enabling activities and reports, including conducting of a comprehensive preclinical literature search on effects of SP1707 in epilepsy;
      • Together with Shackelford’s SAB, designed and drafted a Phase 2 protocol synopsis for inclusion in the Pre-IND briefing book for the FDA;
      • Prepared for and held two critical SAB meetings based upon feedback received from FDA with respect to our Pre-IND package, resulting in several ongoing actions to improve the submission for the upcoming IND;
      • Established further enhancements for provisional patent strength and augmenting future clinical investigator engagement;
      • Conducted third-party, independent company valuation for forthcoming financing;

      And of course, of greatest importance:

      • Completed a deep data dive on additional real-world experience from Dr. Shackelford’s patient records which produced strong evidence of the potential of SP1707 and gave us further insights into other potential indications beyond our initial target.

      dd5a156d-fa66-b944-8ed9-77e1c233a747.jpg

      Developing an actual medicine that medical doctors prescribe is an extremely expensive exercise as you know. If successful, however, medicines are amongst the most valuable assets anyone can own, which is why pharmaceutical companies are amongst the most valuable companies in the world.

      In our case, we are most fortunate to have Dr. Shackelford’s real-world experience. A significant portion of the expense in drug development is found in the discovery process, which generally happens in a chemistry lab. As you know, we are unique. Thanks to Dr. Shackelford’s work, our discoveries come from actual patient interactions from his medical practice. However, the next stage, which is the regulatory pathway, is expensive, and this path is determined by the FDA.

      Our Phase 2 trial will cost approximately $30 million. This covers the manufacture of clinical trial supplies, which is significant. It also encompasses all the necessary work establishing trial sites and enrolling participants into the trial based upon the criteria accepted by the FDA and Institutional Review Boards. Our trial is expected to run approximately 24 months, with interim results announced halfway through the trial.

      Our plan is to tackle this funding requirement in two steps, starting with a Regulation A crowdfunding round, just like our initial financing. We expect this new round will launch in the coming days. As investors in Shackelford, we will open this new offering to our existing shareholders first, so please keep your eyes open for our next email, where we expect to share more details along with an invitation to participate if you wish1.

      In anticipation of this financing, we engaged a respected international firm that focuses specifically on pharmaceutical company valuations. This independent, 3rd-party opinion valued our company between USD $70-million and USD $187 million. Recognizing the soft macro market conditions that have affected the capital markets over the last year, we chose to value our company at the lower end of this valuation, and set the price at USD $1.50 per share, which correlates to a pre-raise market cap of about USD $70-million.

      Our Regulation A funding round will be open for up to a total of USD $12 million.

      We are working on the balance of the funding by targeted institutional investors and funds, and we are in discussions with several parties who are interested in our target indication, our team and our approach, and have started due diligence to learn more about Shackelford and the opportunity. While we are committed to helping as many people as we can who suffer from epilepsy, we are also committed to making sure that our shareholders have an opportunity to benefit from the increase in value of our Company as we progress as well. This may be as a private, or public entity, depending upon how we can best raise capital and maximize shareholder value.

      As mentioned above, we will be hosting an investor webinar early this year, where I will invite key members of our team to attend. This will allow anyone who attends the opportunity to hear directly from the Shackelford team, and more importantly, provide a venue to ask questions and learn more about what I have described above. I hope you are all able to join us. We’ll be sure to record it and share it as well if you cannot.

      THANK YOU again, to each of you reading this and for your support, without which we would not be here. We are on the precipice of an exciting new chapter in our Company’s development, and we owe much of this progress to you.

      On behalf of YOUR team, I wish everyone an incredible 2023!!

      Onwards!!

      ed8ce33a-4add-cd97-12b9-e1183ee248df.jpg

      Mark Godsy
      Co-Founder, CEO and Chairman

       

      Contact US  

      If you have any questions or wish to connect for any reason, please feel free to reach out to us via email at investors@shackelfordpharma.com or by calling us at 1-888-377-4225 Ext.1.


      Thank you for taking the time to read our update - and for your ongoing support of Shackelford Pharma.

      [1] This is not an offer for sale of shares. Appropriate offering documents will be issued when a financing is launched.

      Shackelford Pharma.PNG

       

      image.png

    • MemberSupport

      Posted

      This article was written by Tori Bedford on January 5th, 2023. Thanks, Tori!

      While the state’s marijuana business continues to boom, cannabis growers in Massachusetts — already facing tough business setbacks in a competitive and volatile market — are scrambling to ward off a rapidly spreading and highly infectious crop disease, one with the power to wipe out entire companies.

      “It’s like the tenth plague for the cannabis industry,” said Peter Grinspoon, a medical cannabis specialist at Massachusetts General Hospital. “The margins are drying up for anybody growing cannabis. They need this like they need a hole in the head. It’s a nightmare.”

      Hop latent viroid, a plant-specific pathogenic RNA, sucks the THC potency out of cannabis plants, degrading the quality and resulting in significantly smaller yields. It's sometimes referred to as "dudding disease."

      The pathogen has already blighted California’s cannabis crops, resulting in $4 billion annual losses, according to cannabis genetics research company Dark Heart Industries. The pathogen has no known effect on human health, though Grinspoon and other experts say very little research exists.

      Grinspoon says the disease is causing a “total evolution” in the cannabis industry, as manufacturers are forced to adopt more stringent measures to combat it. Their prevention efforts include more rigorous sanitation in grow facilities, regular lab testing, and sourcing plants from pre-tested seed or local stock — steps that come at a cost.

      “If you were cutting corners, I’m sure you have stopped cutting them by now,” Grinspoon said. “It’s not in your economic interests to cut corners when something like this is spreading from crop to crop.”

      Where cost-cutting may come back to haunt growers
      Ed DeSousa, who owns the small wholesale grow facility River Run Gardens in Newburyport, said growers who have always been meticulous about their product have less to worry about. The companies facing the greatest threat now, he said, are the ones that tried to save money by importing “clones” of trendy, out-of-state variants or fell behind on testing and sanitization.

      “Those who decided to take those shortcuts to try to make some money, it's almost like cannabis karma,” DeSousa said. “If you go into this particular line of business and you are looking to maximize your profit at the stake of putting out a solid product, well, this was bound to happen.”


      The virus can be detected through a genetic PCR test, a step that is not required by the Cannabis Control Commission.

      By the time growers notice the signs — stunted and brittle plants, lower THC levels and discolored leaves — it’s too late to stop the spread, Masso said. By that point, growers are essentially left with one option, said Nick Masso, the CEO of Marlborough-based Indo Laboratories, an independent marijuana testing facility.

      “Destroy it. Destroy everything,” he said. “And if you had that anywhere within your facility, you need to do an extremely deep clean. You can’t sell a low-quality product that has no THC, and no one will buy it.”

      On a federal level, cannabis remains illegal, and shipping plants across state lines is prohibited by state law. A gray area in the regulations allows growers to acquire seeds and trimmings or “immature plants” (non-flowering and under eight inches tall) from out-of-state and disclose the plants once they reach the propagation stage.

      “Typically no one really starts with seeds anymore. People usually will get clones from someone to have a little bit more of an advanced starting point,” Masso said. “There are companies out there that get seeds, but they're not always doing genetic testing.”

      A call for stricter cannabis regulation
      Since recreational marijuana was legalized in Massachusetts seven years ago, the industry has accelerated at a breakneck pace, Masso said, with regulators “lacking the bandwidth” to apply additional — and necessary — scrutiny.

      “A lot of it depends on how much effort these companies are willing to put in to actually make sure that they’re being safe in what they’re putting out into the market,” Masso said.

      A 2018 Harvard study demonstrated inaccurate and wildly varied results from state-certified marijuana testing facilities in Washington state. An investigation conducted last year by journalists from Commonwealth Magazine showed inconsistencies in levels of THC and contaminants present in cannabis sold in Massachusetts.

      The spread of hop latent viroid is a call to action for companies — and regulators — who have let protocols fall through the cracks in recent years, Masso said. Now, companies that didn’t want to play by the rules face serious consequences.

      “There’s something very poetic about it,” he said. “I don’t take pleasure in other people's misfortune, but sometimes there's companies out there that deserve it. I just hope that someone doesn't have to get hurt for them to learn their damn lesson.”

      Masso says regulation is vital in a market where many companies may just not know better, making mistakes without realizing the potential consequences. He works with 35 clients around the state, and says his lab has detected hop latent viroid at three locally-based marijuana grow facilities in the past three years.

      “I’m suspicious that there are many, many more companies that have experienced this, because you’ll see the THC levels drop from the twenties to the teens,” Masso said. “It doesn’t feel like enough people in the industry understand the gravity of what this could mean.”

      Massachusetts law requires marijuana testing labs to be accredited through a process that requires audits, background checks and quality assurance tests, but labs aren’t required to receive accreditation for every single test they conduct, Masso says.

      “Every single thing that we do is accredited, but the clients don't know any different when it comes to labs,” he said. “That leaves a lot of room for bad actors to come into the space who don't give a damn about the science, they just want to make money.”

      The state’s cannabis production industry is now the highest valued agricultural crop at $362 million annual wholesale value, according to trade publication.

      Masso says his hope is that the financial threat from hop latent viroid will force the industry to focus on consumers who use marijuana for medical purposes and could suffer if products fall off the market.

      “The cannabis industry built itself on being medicinal, that’s where it got its roots,” he said. “Now it's become just a commodity and people have forgotten that it was all about treating patients, not just about getting people high and making money.”

    • MemberSupport

      Posted

      Article by Tori Bedford; January 5th, 2023

      While the state’s marijuana business continues to boom, cannabis growers in Massachusetts — already facing tough business setbacks in a competitive and volatile market — are scrambling to ward off a rapidly spreading and highly infectious crop disease, one with the power to wipe out entire companies.

      “It’s like the tenth plague for the cannabis industry,” said Peter Grinspoon, a medical cannabis specialist at Massachusetts General Hospital. “The margins are drying up for anybody growing cannabis. They need this like they need a hole in the head. It’s a nightmare.”

      Hop latent viroid, a plant-specific pathogenic RNA, sucks the THC potency out of cannabis plants, degrading the quality and resulting in significantly smaller yields. It's sometimes referred to as "dudding disease."

      The pathogen has already blighted California’s cannabis crops, resulting in $4 billion annual losses, according to cannabis genetics research company Dark Heart Industries. The pathogen has no known effect on human health, though Grinspoon and other experts say very little research exists.

      Grinspoon says the disease is causing a “total evolution” in the cannabis industry, as manufacturers are forced to adopt more stringent measures to combat it. Their prevention efforts include more rigorous sanitation in grow facilities, regular lab testing, and sourcing plants from pre-tested seed or local stock — steps that come at a cost.

      “If you were cutting corners, I’m sure you have stopped cutting them by now,” Grinspoon said. “It’s not in your economic interests to cut corners when something like this is spreading from crop to crop.”

      Where cost-cutting may come back to haunt growers
      Ed DeSousa, who owns the small wholesale grow facility River Run Gardens in Newburyport, said growers who have always been meticulous about their product have less to worry about. The companies facing the greatest threat now, he said, are the ones that tried to save money by importing “clones” of trendy, out-of-state variants or fell behind on testing and sanitization.

      “Those who decided to take those shortcuts to try to make some money, it's almost like cannabis karma,” DeSousa said. “If you go into this particular line of business and you are looking to maximize your profit at the stake of putting out a solid product, well, this was bound to happen.”


      The virus can be detected through a genetic PCR test, a step that is not required by the Cannabis Control Commission.

      By the time growers notice the signs — stunted and brittle plants, lower THC levels and discolored leaves — it’s too late to stop the spread, Masso said. By that point, growers are essentially left with one option, said Nick Masso, the CEO of Marlborough-based Indo Laboratories, an independent marijuana testing facility.

      “Destroy it. Destroy everything,” he said. “And if you had that anywhere within your facility, you need to do an extremely deep clean. You can’t sell a low-quality product that has no THC, and no one will buy it.”

      On a federal level, cannabis remains illegal, and shipping plants across state lines is prohibited by state law. A gray area in the regulations allows growers to acquire seeds and trimmings or “immature plants” (non-flowering and under eight inches tall) from out-of-state and disclose the plants once they reach the propagation stage.

      “Typically no one really starts with seeds anymore. People usually will get clones from someone to have a little bit more of an advanced starting point,” Masso said. “There are companies out there that get seeds, but they're not always doing genetic testing.”

      A call for stricter cannabis regulation
      Since recreational marijuana was legalized in Massachusetts seven years ago, the industry has accelerated at a breakneck pace, Masso said, with regulators “lacking the bandwidth” to apply additional — and necessary — scrutiny.

      “A lot of it depends on how much effort these companies are willing to put in to actually make sure that they’re being safe in what they’re putting out into the market,” Masso said.

      A 2018 Harvard study demonstrated inaccurate and wildly varied results from state-certified marijuana testing facilities in Washington state. An investigation conducted last year by journalists from Commonwealth Magazine showed inconsistencies in levels of THC and contaminants present in cannabis sold in Massachusetts.

      The spread of hop latent viroid is a call to action for companies — and regulators — who have let protocols fall through the cracks in recent years, Masso said. Now, companies that didn’t want to play by the rules face serious consequences.

      “There’s something very poetic about it,” he said. “I don’t take pleasure in other people's misfortune, but sometimes there's companies out there that deserve it. I just hope that someone doesn't have to get hurt for them to learn their damn lesson.”

      Masso says regulation is vital in a market where many companies may just not know better, making mistakes without realizing the potential consequences. He works with 35 clients around the state, and says his lab has detected hop latent viroid at three locally-based marijuana grow facilities in the past three years.

      “I’m suspicious that there are many, many more companies that have experienced this, because you’ll see the THC levels drop from the twenties to the teens,” Masso said. “It doesn’t feel like enough people in the industry understand the gravity of what this could mean.”

      Massachusetts law requires marijuana testing labs to be accredited through a process that requires audits, background checks and quality assurance tests, but labs aren’t required to receive accreditation for every single test they conduct, Masso says.

      “Every single thing that we do is accredited, but the clients don't know any different when it comes to labs,” he said. “That leaves a lot of room for bad actors to come into the space who don't give a damn about the science, they just want to make money.”

      The state’s cannabis production industry is now the highest valued agricultural crop at $362 million annual wholesale value, according to trade publication.

      Masso says his hope is that the financial threat from hop latent viroid will force the industry to focus on consumers who use marijuana for medical purposes and could suffer if products fall off the market.

      “The cannabis industry built itself on being medicinal, that’s where it got its roots,” he said. “Now it's become just a commodity and people have forgotten that it was all about treating patients, not just about getting people high and making money.”

    • MemberSupport

      Posted

      LAS VEGAS, NV / ACCESSWIRE / December 5, 2022 / Planet 13 Holdings Inc. (CSE:PLTH) (OTCQX:PLNHF) ("Planet 13" or the "Company"),a leading vertically-integrated multi-state cannabis company, announces that its subsidiary MM Development Company, Inc. has received approval for a Nevada consumption lounge from the Nevada Cannabis Compliance Board ("CCB"). The Planet 13 Entertainment Complex will be the first of its kind space where consumers can watch products being made, purchase and consume all under one roof. This luxurious, tourist friendly lounge, close to the Las Vegas Strip is expected to elevate the already incredible Planet 13 experience.

      "We are thrilled to be moving forward with our plan to bring a world-class cannabis consumption lounge next to the Las Vegas Strip," said Larry Scheffler, Co-CEO of Planet 13. "Planet 13 has always been about offering new and one-of-a-kind immersive experiences for customers. We look forward to once again pushing the envelope and expanding people's minds about what cannabis can be."
      For more information on Planet 13, visit the investor website.

      About Planet 13
      Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations in Las Vegas and in Orange County, California. Planet 13 also holds a medical marijuana treatment center license in Florida and a 49% interest in Planet 13 Illinois which holds a provisional Social-Equity Justice Involved dispensing license in the Chicago-region of Illinois. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13's shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and on the OTCQX under the symbol PLNHF.
      Cautionary Note Regarding Forward-Looking Information

      This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and are forward-looking statements. In this news release, forward looking-statements relate to the Company's design, construction, and operation of a Nevada consumption lounge.

      These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents needed to operate our business; risks associated with COVID-19 and other infectious diseases presenting as major health issues; fluctuations in general macroeconomic conditions; inflationary pressures; fluctuations in securities markets; expectations regarding the size of the cannabis market in the states in which we currently operate in or contemplate future operations and changing consumer habits in such states; the ability of the Company to successfully achieve its business objectives; the ability of the Company to integrate the NGW business and realize any benefits from the acquisition; plans for expansion; political and social uncertainties including international conflict; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the states in which we currently operate in or contemplate future operations; employee relations and other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission at www.sec.gov and on the Company's issuer profile on SEDAR at www.sedar.com and in the Company's periodic reports subsequently filed with the U.S. Securities and Exchange Commission and on SEDAR. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

      The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through licensed subsidiary entities in states that have legalized marijuana operations, however, these activities are currently illegal under United States federal law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
      No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

      For further inquiries, please contact:
      LodeRock Advisors Inc., Planet 13 Investor Relations
      mark.kuindersma@loderockadvisors.com
      Robert Groesbeck or Larry Scheffler
      Co-Chief Executive Officers
      ir@planet13lasvegas.com

      SOURCE: Planet 13 Holdings Inc.
      You can view this article online using the following link: https://www.accesswire.com/730051/Planet-13-Announces-Approval-for-Consumption-Lounge-License-a-Highly-Anticipated-Addition-to-the-World-Renowned-Las-Vegas-SuperStore-Experience
       

    • MemberSupport

      Posted

      Awesome Verticle Farming Units (VFUs)... these will change the nature of the medical C+H industries!

  • American Association of Cannabis and Hemp Value Chain Organizations
  • American Association of Cannabis and Hemp Value Chain Organizations
  • American Association of Cannabis and Hemp Value Chain Organizations


  • Member Statistics

    • Total Members
      189
    • Most Online
      228

    Find 420
    Newest Member
    Find 420
    Joined
×
×
  • Create New...

Important Information

(terms) (privacy) (guidelines) (cookies)